Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis

Prostate Cancer and Prostatic Diseases volume 21, pages 516–523 (2018)Cite this article

Subjects

Abstract

Background

Patients with metastatic prostate cancer have poor prognosis. In this study, we compared the addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to standard ADT vs. ADT alone for patients with mHSPC in terms of overall survival (OS), failure-free survival (FFS), and adverse events.

Methods

We searched PubMed and performed a network meta-analysis to generate probabilistic inferences and provide efficacy rankings in terms of posterior hazard ratios with 95% credible intervals (CrI), surface under the cumulative ranking curve (SUCRA), probability better than competing treatments, and probability best.

Results

Seven trials were included (LATITUTE, STAMPEDE, CHAARTED, GETUG-AFU15, ZAPCA, CALGB 90202, and MRC PR05). Compared to ADT alone, evidence suggests abiraterone + ADT (OS HR: 0.60; 95% CrI: 0.50–0.71, FFS HR: 0.31; 95% CrI: 0.25–0.38) could be superior in terms of OS and FFS compared to docetaxel + ADT (OS 0.74; 95% CrI: 0.63–0.86, FFS 0.62; 95% CrI: 0.53–0.74), bisphosphonate + ADT (OS: 0.87; 95% CrI: 0.75–1.00, FFS 0.87; 95% CrI: 0.75–1.00), celecoxib + ADT (OS: 0.91; 95% CrI: 0.71–1.17, FFS: 0.86; 95% CrI: 0.68–1.08), or triple combinations. Abiraterone + ADT suggests improved survival with 97% certainty for a 19% reduction in risk of death compared to docetaxel + ADT (HR: 0.81; 95% CrI: 0.66–1.00).

Discussion

Addition of abiraterone to standard ADT may possibly outperform the addition of docetaxel, bisphosphonates, celecoxib, or combinations to standard ADT in terms of OS and FFS.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.

    Article  CAS  Google Scholar 

  2. WHO. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. International Agency for Research on Cancer, World Health Organization. 2012. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx.

  3. Siegel RL,Miller KD,Jemal A, Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.

    Article  Google Scholar 

  4. American Cancer Society. Survival rates for prostate cancer. 2017. https://www.cancer.org/cancer/prostate-cancer/detection-diagnosis-staging/survival-rates.html Accessed 10 Sep 2017.

  5. Huggins C, Hodges CV Studies on Prostatic Cancer. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1. http://cancerres.aacrjournals.org/content/1/4/293 Accessed 10 Sep 2017.

  6. Huggins C, Stevens RE, Hodges CV. Studies on prostatic cancer II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43:209–23. https://doi.org/10.1001/archsurg.1941.01210140043004.

    Article  CAS  Google Scholar 

  7. Parker C, Gillessen S, Heidenreich A, Horwich A. cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(suppl 5):v69–77. https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdv222.

    Article  Google Scholar 

  8. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352–60. http://www.nejm.org/doi/10.1056/NEJMoa1704174.

    Article  CAS  Google Scholar 

  9. Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): A randomised, Open-label, Phase 3 trial. Lancet Oncol. 2013;14:149–58.

    Article  CAS  Google Scholar 

  10. Gravis G, Boher JM, Joly F, Soulié M, Albiges L, Priou F, et al. Androgen deprivation therapy (ADT) plus docetaxel versus adt alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 Trial. Eur Urol. 2016;70:256–62.

    Article  CAS  Google Scholar 

  11. Sweeney CJ, Chen Y-H, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737–46. http://www.nejm.org/doi/10.1056/NEJMoa1503747.

    Article  CAS  Google Scholar 

  12. Kamba T, Kamoto T, Maruo S, Kikuchi T, Shimizu Y. A phase III multicenter, randomized, contro lled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial. Int J Clin Oncol. 2017;22:166–73.

    Article  Google Scholar 

  13. Smith MR, Halabi S, Ryan CJ, Hussain A, Vogelzang N, Stadler W, et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (Alliance). J Clin Oncol. 2014;32:1143–50.

    Article  CAS  Google Scholar 

  14. Dearnaley DP,Mason MD,Parmar MKB,Sanders K,Sydes MR, Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol. 2009;10:872–6. https://doi.org/10.1016/S1470-2045(09)70201-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Dearnaley DP, Sydes MR, Mason MD, Stott M, Powell CS, Robinson ACR, et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst. 2003;95:1300–11. https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djg038.

    CAS  Google Scholar 

  16. James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone the rapy. N Engl J Med. 2017;377:338–51. http://www.nejm.org/doi/10.1056/NEJMoa1702900.

  17. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163–77.

    Article  CAS  Google Scholar 

  18. Mason MD, Clarke NW, James ND, Dearnaley DP, Spears MR, Ritchie AWS, et al. Adding celecoxib with or without zoledronic acid for hormone-naïve prostate cancer: long-term survival results from an adaptive, multiarm, multistage, platform, randomized controlled trial. J Clin Oncol. 2017;35:1530–41.

    Article  CAS  Google Scholar 

  19. Salanti G, Ades A, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64:163–71. http://www.ncbi.nlm.nih.gov/pubmed/20688472.

    Article  Google Scholar 

  20. Plummer M. RJAGS version 3-11: Bayesian graphical models using MCMC. 2012.

  21. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria; 2017. https://www.r-project.org/. Accessed March 2017.

  22. Moher D,Liberati A,Tetzlaff J,Altman DG, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med [Internet]. 2009;6:e1000097. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2707599&tool=pmcentrez&rendertype=abstract.

    Article  Google Scholar 

  23. Matthew RS et al. LBA31_PR - Adding abiraterone acetate plus prednisolone (AAP) or docetaxel for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): directly randomised data from STAMPEDE (NCT00268476). ESMO. 2017. http://www.esmo.org/Oncology-News/Adding-abiraterone-acetate-or-docetaxel-plus-prednisone-to-standard-of-care-in-patients-with-high-risk-prostate-cancer. Accessed 11 Sep 2017.

  24. Rydzewska LHM, Burdett S, Vale CL, Clarke NW, Fizazi K, Kheoh T, et al. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. Eur J Cancer. 2017;84:88–101. http://linkinghub.elsevier.com/retrieve/pii/S0959804917311103.

    Article  CAS  Google Scholar 

  25. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ. 2010;340:c221. http://www.bmj.com/cgi/doi/10.1136/bmj.c221.

    Article  Google Scholar 

  26. ClinicalTrials.gov. A Phase III of ADT + /− Docetaxel + /- Local RT + /− Abiraterone Acetate in Metastatic Hormone-naïve Prostate Cancer. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01957436. Accessed 11 Sep 2017.

  27. ClinicalTrials.gov. Enzalutamide in first-line androgen deprivation therapy for metastatic prostate cancer. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02446405. Accessed 11 Sep 2017.

  28. ClinicalTrials.gov. A study of enzalutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT in patients with metastatic hormone sensitive prostate cancer (mHSPC). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02677896. Accessed 11 Sep 2017.

  29. ClinicalTrials.gov. ODM-201 in addition to standard ADT and docetaxel in metastatic castration sensitive prostate cancer. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02799602. Accessed 11 Sep 2017.

Download references

Author information

Authors and Affiliations

  1. Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK

    Pui San Tan

  2. Clinical Oncology Sector, Faculdade de Medicina do ABC, Santo André, Brazil

    Pedro Aguiar Jr.

  3. Population Health Sciences and Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA

    Benjamin Haaland

  4. Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA

    Gilberto Lopes

Authors
  1. Pui San Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pedro Aguiar Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Benjamin Haaland
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gilberto Lopes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pui San Tan.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tan, P.S., Aguiar, P., Haaland, B. et al. Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis. Prostate Cancer Prostatic Dis 21, 516–523 (2018). https://doi.org/10.1038/s41391-018-0055-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41391-018-0055-8

This article is cited by

Search

Advanced search

Quick links